Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.48 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TGM1 | P22735 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16525824 | 0.87 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14068102 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL5787375 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1870162 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14388099 | 0.86 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL70762 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2621378 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2621382 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL70761 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL603957 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| US-12486273-B2 | Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4642778-A1 | LSD1 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| EP-3888657-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-115135642-B | Inhibitors of EGFR mutant forms | 缆图药品公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-12172983-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4476204-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | Theras, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-9199982-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150284390-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-9096600-B2 | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| WO-2015027124-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015027124-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2655374-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2012087881-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | SMN1; SMN2 4552/4885NPC1 2696/4885RAB9A 979/4885 |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | SMN1; SMN2 2711/4885NPC1 1501/4885RAB9A 409/4885 |
| US-20150284390-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | SMN1; SMN2 2711/4885NPC1 1501/4885RAB9A 409/4885 |
| US-12172983-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4618/4885NPC1 1359/4885RAB9A 486/4885 |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | SMN1; SMN2 2476/4885NPC1 802/4885RAB9A 1982/4885 |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | SMN1; SMN2 4552/4885NPC1 2696/4885RAB9A 979/4885 |
| US-12486273-B2 | Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease | AQP1, HRH2, HRH1 | SMN1; SMN2 2029/4885NPC1 3149/4885RAB9A 1108/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4618/4885NPC1 1359/4885RAB9A 486/4885 |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | SMN1; SMN2 4552/4885NPC1 2696/4885RAB9A 979/4885 |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | SMN1; SMN2 4350/4885NPC1 3172/4885RAB9A 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.